Automated Multiplex CRISPR-Cas12l (CasLambda) Vector Foundry Cap Rate 2026

Underwrite GMP Class A/B continuous synthetic ultra-compact Cas12l (CasLambda, 800 amino acid micro-nuclease) dual-targeting gene editing vector suites, $595/sqft base lease rates, and exit cap rates.

Underwriting Assumptions

CasLambda Cleanroom Footprint (sqft)

NNN Base Lease Rate ($/sqft/yr)

Turnkey GMP CasLambda Foundry Acquisition ($)

Target Exit Capitalization Rate (%)

Projected Economics

Net Operating Income (NOI)

Going-In Capitalization Rate

Stabilized Institutional Valuation